1. Home
  2. OSUR vs SGMT Comparison

OSUR vs SGMT Comparison

Compare OSUR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

HOLD

Current Price

$3.58

Market Cap

207.2M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.13

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSUR
SGMT
Founded
2000
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.2M
169.4M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
OSUR
SGMT
Price
$3.58
$7.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$3.00
$26.13
AVG Volume (30 Days)
596.2K
2.8M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,064,000.00
$2,000,000.00
Revenue This Year
$4.48
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$3.32
52 Week High
$3.76
$11.41

Technical Indicators

Market Signals
Indicator
OSUR
SGMT
Relative Strength Index (RSI) 73.38 51.92
Support Level $2.87 $7.09
Resistance Level N/A $7.20
Average True Range (ATR) 0.17 0.47
MACD 0.05 -0.16
Stochastic Oscillator 97.97 35.13

Price Performance

Historical Comparison
OSUR
SGMT

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: